Basel, Switzerland, 7 November 2012 – Lonza, a leading custom manufacturer of biological therapeutics, announced today the launch of two new 360° virtual tours. The new digital tours provide a comprehensive view of Lonza Bioscience’s facilities in Walkersville, MD (USA) (www.lonza.com/Walkersville) and Houston, TX (USA) (www.lonza.com/Houston). The tours include views of cGMP suites, laboratories, and business support functions at these sites which are engaged in cell therapy, gene therapy, viral vaccine fill/finish, and therapeutic media production.
Lonza was able to capture the daily development and production operations within these suites, laboratories, and production areas using state-of-the-art technology. This digital interface has been designed to allow clients everywhere to conveniently explore these facilities at their leisure, while avoiding costly travel.
“Both Maryland and Texas are ideal locations for state-of-the-art biotechnology facilities and we are pleased to present these new virtual tours along with the existing virtual tour of our facility in Singapore to allow our customers and partners to fully explore these global facilities from the web”, said Dave Smith, Head of the Lonza Bioscience Services business. “We value the importance of a strong global presence in today’s market and have invested in these virtual tours to benefit our global customers and expand awareness of our outstanding capabilities.”
For further information and direct access to Lonza’s Virtual Tours, please visit www.lonzavirtualtours.com
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.692 billion. Further information can be found at www.lonza.com.
Lonza Walkersville Inc.
Tel +1 301 378 1555
Fax +1 301 845 4024
Lonza Group Ltd
Tel +1 201 316 9413
Fax +1 201 696 3533